Brief: Helix Biopharma Corp. Announces Regulatory Approval To Dose Patients In A Phase II Randomized Study of L-DOS47 With Vinorelbine And Cisplatin
10/04/2018 12:45
April 10 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. ANNOUNCES REGULATORY APPROVAL TO
DOSE
PATIENTS IN A PHASE II RANDOMIZED STUDY OF L-DOS47 WITH
VINORELBINE AND CISPLATIN
* ALL NECESSARY REGULATORY AND ETHICS APPROVALS HAVE BEEN
RECEIVED
TO DOSE FIRST PATIENT IN ITS LDOS003 TRIAL IN UKRAINE
Source text for Eikon: ID:nGNX2vql0G
Further company coverage: HBP.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020